SUVRETTA CAPITAL MANAGEMENT, LLC 13D and 13G filings for Fulcrum Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-01-06 4:50 pm Purchase |
2024-12-27 | 13G | Fulcrum Therapeutics, Inc. FULC |
SUVRETTA CAPITAL MANAGEMENT, LLC | 3,404,612 6.300% |
2,221,821 (+187.85%) |
Filing |
| 2024-11-14 4:25 pm Sale |
2024-09-30 | 13G | Fulcrum Therapeutics, Inc. FULC |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,182,791 2.200% |
-4,336,090 (-78.57%) |
Filing |
| 2024-02-13 12:08 pm Purchase |
2023-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
SUVRETTA CAPITAL MANAGEMENT, LLC | 5,518,881 8.900% |
1,244,078 (+29.10%) |
Filing |
| 2023-02-13 10:15 am Purchase |
2022-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
SUVRETTA CAPITAL MANAGEMENT, LLC | 4,274,803 8.200% |
1,899,232 (+79.95%) |
Filing |
| 2022-02-11 4:19 pm Purchase |
2021-12-31 | 13G | Fulcrum Therapeutics, Inc. FULC |
SUVRETTA CAPITAL MANAGEMENT, LLC | 2,375,571 5.900% |
578,653 (+32.20%) |
Filing |
| 2021-08-10 5:05 pm Purchase |
2021-08-04 | 13G | Fulcrum Therapeutics, Inc. FULC |
SUVRETTA CAPITAL MANAGEMENT, LLC | 1,796,918 5.500% |
1,796,918 (New Position) |
Filing |